#### Cardiovascular Endorsement Maintenance Steering Committee February 15-16, 2011 9:00 am ET

#### Conference Center of the American Immigration Lawyers Association 1331 G Street NW Washington, DC 20005

Please use the following information to access the conference call line:

Participant Dial-in Number: 1-888-417-2254 Conference ID: 2978114

#### DRAFT AGENDA

#### Day 1 – February 15

9:00 am	Welcome and Introductions
5.00 um	Helen Burstin, MD, MPH Senior Vice President of Performance Measures
	Ray Gibbons, MD (Chair)
	Mary George, MD, MSPH (Vice-Chair)
	Reva Winkler, MD, MPH, Senior Program Director
	Ashley Morsell, MPH, Project Manager
	Kathryn Streeter, MS, Program Manager
	Disclosures of Interest
	Ann Hammersmith, General Counsel
9:30 am	<b>Project Introduction and Overview of Evaluation Process</b>
	Dr. Winkler
	Ms. Morsell
	Ms. Streeter
9:45 am	Consideration of Candidate Measures:
	Coronary Artery Disease (CAD) – Secondary Prevention
	Brief Introduction of Measures by Developers
	• 0073 IVD: blood pressure management (NCQA)
	• 1486 CAD: blood pressure management (AMA – PCPI)
	• 0068 IVD: use of aspirin or antithrombotics ( <i>NCQA</i> )
	• 0067 CAD: antiplatlet therapy (AMA – PCPI)
10:50 am	Break

11:00 am	<ul> <li><u>CAD – Secondary Prevention (con't)</u></li> <li>0075 IVD- complete lipid profile and LDL control &lt;100 (NCQA)</li> <li>0074 CAD: drug therapy (AMA – PCPI)</li> <li>0066 CAD: ACE/ARB therapy (AMA – PCPI)</li> <li>0070 CAD: beta blocker – prior MI (AMA – PCPI)</li> <li>0071 AMIpersistence of BB therapy (NCQA)</li> </ul>
12:15 pm	NQF Member/Public Comment
12:30 pm	Lunch Break
1:00 pm	<ul> <li>Consideration of Candidate Measures <u>CAD – Secondary Prevention (con't)</u></li> <li>0065 CAD: symptoms and assessment (AMA – PCPI)</li> <li>0076 optimal vascular care (MCM)</li> </ul>
2:00 pm	<ul> <li><u>Acute Myocardial Infarction (AMI) –Emergency Department (ED)</u></li> <li>Brief Introduction of Measures by Developers</li> <li>0289 Median to ECG (CMS)</li> <li>0132 Aspirin at arrival for AMI (CMS)</li> <li>0286 Aspirin at arrival (CMS)</li> <li>0163 Primary PCI within 90 minutes of arrival (CMS)</li> </ul>
3:00 pm	Break
3:10 pm	<ul> <li>Consideration of Candidate Measures <ul> <li><u>AMI –ED (con't)</u></li> <li>0164 Fibrinolytic therapy received within 30 minutes (<i>CMS</i>)</li> <li>0288 Fibrinolytic therapy received within 30 minutes of ED arrival (<i>CMS</i>)</li> <li>0287 Median time to fibrinolysis (<i>CMS</i>)</li> <li>0290 Median time to transfer to another facility (<i>CMS</i>)</li> </ul> </li> <li><u>AMI – HOSPITAL</u> Brief Introduction of Measures by Developers <ul> <li>0160 D to block block and the block blo</li></ul></li></ul>
	<ul> <li>0160 Beta blocker prescribed at discharge (<i>CMS</i>)</li> <li>0142 Aspirin prescribed at discharge for AMI (<i>CMS</i>)</li> <li>0137 ACEI/ARB at discharge for AMI (<i>CMS</i>)</li> </ul>
5:00 pm	NQF Member/Public Comment
5:15 pm	Adjourn

### <u>Day 2 – February 16</u>

8:00 am	Welcome, Recap of Day One Dr. Gibbons Dr. George
8:10 am	<ul> <li>Consideration of Candidate Measures <ul> <li><u>AMI – HOSPITAL</u> (con't)</li> </ul> </li> <li>Brief Introduction of Measures by Developers</li> <li>961 AMI hospital composite (CMS)</li> <li>0230 AMI 30-day mortality (CMS)</li> <li>0282 Angina without procedure (PQI 13) (AHRQ)</li> </ul>
9:45 am	<ul> <li>Consideration of Candidate Measures Percutaneous Coronary Interventions (PCI) Brief Introduction of Measures by Developers <ul> <li>0355 Bilateral cardiac cath rate (IQI 25) (AHRQ)</li> <li>0133 PCI mortality (ACC)</li> </ul></li></ul>
10:30 am	<ul> <li>Break</li> <li>Percutaneous Coronary Interventions (PCI) (con't)</li> <li>1495 P2Y12 inhibitor at discharge for PCI (ACCF)</li> <li>1493 Aspirin at discharge for PCI (ACCF)</li> <li>1498 Statins at discharge for PCI (ACCF)</li> </ul>
11:30 pm	NQF Member/Public Comment
11:45 pm	Lunch break
12:15 am	<ul> <li>Consideration of Candidate Measures <ul> <li><u>Cardiac Rehabilitation</u></li> <li>1496 Cardiac rehab – safety standards (AACPR / ACCF / AHA)</li> <li>1494 Cardiac rehab – response to therapy (AACPR / ACCF / AHA)</li> <li>1497 Cardiac rehab – risk for adverse events (AACPR / ACCF / AHA)</li> <li>960 Cardiac rehab composite (AACPR / ACCF / AHA)</li> </ul> </li> </ul>
1:30 pm	Measures Requesting Retirement of Endorsement Review of NQF Portfolio of Measures for CAD, AMI, PCI
1:45 pm	Break

- 2:00 pm Related and Competing Measures Measure Harmonization/ Selection of Best Measure from Among Competing Measures
- 2:45 pm Gaps in Measures to Describe an Episode of Care
- 3:00 pm NQF Member/Public Comment
- 3:15 pm Next Steps/Timeline for Project
- 3:30 pm Adjourn